Notable Labs, a San Francisco, CA-based mission-driven company focused on advancing personalized cancer treatments, closed a $10m Series A financing.
The round was led by Builders VC, with participation from existing investors. In conjunction with the funding, Jim Kim, founding member and general partner of Builders VC, joined Notable’s board of directors.
The company, which has raised $17m in total funding, will use the capital to build its technology platform and team, as well as support a growing number of clinical feasibility studies in blood cancers.
Founded in 2014 by Matthew De Silva, Chief Executive Officer, and Pete Quinzio, Notable Labs is developing a personalized treatment service for people with cancer that prioritizes combinations of FDA-approved treatments that can be immediately prescribed by a doctor.
Focusing on individual patients and existing treatments, the company is discovering novel uses of drugs and defining mechanisms underlying development of cancer progression and drug resistance.